Half year report 2023
A unique network with strong partners.
Key figures
The growth of sales of the Galenica Group in the first half of 2023 was pleasing, rising by 5.5% to CHF 1,851.2 million.
Financial key figures
Net sales
in million CHF
EBIT adjusted
in million CHF
Dividend
in CHF per share
Management report
Galenica achieves strong sales growth in the first half of 2023
In the first half of 2023, Galenica increased consolidated net sales by 5.5% compared to the first half of the previous year to CHF 1,851.2 million. The “Logistics & IT” segment in particular posted strong growth of 5.8%. The “Products & Care” segment also performed well with sales growth of 4.2%, supported by the strong performance of 19.8% in the “Products & Brands” sector.
«The Group’s bricks-and-mortar pharmacies play a key role in Galenica’s push to integrate and network healthcare in Switzerland.»
Virginie Pache, Chief Pharmacies Officer